MEXICO CITY, Jan. 12 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company") announced that on January 9, 2009, the Company signed an agreement with IXE Casa de Bolsa, S.A. de C.V. to act as the market maker for the Company's outstanding shares, thus becoming another company to participate in the market maker program. The contract will become valid upon approval of the Mexican Stock Exchange (Bolsa Mexicana de Valores) and will be in effect for a minimum period of 12 months from the date of the agreement.
Less than 6 months since becoming a public company, Genomma Lab seeks to leverage the benefits of the modernizing Mexican markets via the market-maker program. The Company expects that its incorporation into this program will allow for increased share liquidity.
With its incorporation into the market-maker program and together with the Share Repurchase program approved by the Board of Directors, Genomma Lab reaffirms its commitment to provide higher liquidity for its shares.
Company Description
Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico with international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share.
Genomma Lab performed its Initial Public Offering in June 2008, through a combined offering (mainly primary) and is listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).
Web Site: http://www.genommalab.com/
Investor Relations Contact:
Tel: +52 (55) 5081 0000 Ext. 4250
E-mail:
